Artwork
iconShare
 
Manage episode 386763409 series 3256997
Content provided by Clinical Care Options, LLC and Clinical Care Options. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clinical Care Options, LLC and Clinical Care Options or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

In this episode, Jacqueline S. Garcia, MD, discusses novel agents and strategies in clinical trial development for treating patients with myelofibrosis, including:

  • Navitoclax (BCL-XL/BCL-2 inhibitor)
  • Pelabresib (BET inhibitor)
  • Imetelstat (telomerase inhibitor)
  • Luspatercept (erythroid maturation agent)
  • Additional strategies

Presenter:

Jacqueline S. Garcia, MD
Assistant Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Link to the full program here. https://bit.ly/47z8WCV

  continue reading

204 episodes